Background. Asymptomatic left ventricular hypertrophy (LVH) is highly prevalent and associated with an adverse outcome in renal transplant recipients (RTRs). Nonetheless, there are currently no available studies analyzing the effect of LVH regression on solid clinical endpoints in these patients. Methods. This study is the prospective observational extension of two randomized controlled trials aimed at assessing the effect of active intervention on post-transplant LVH in RTRs. We evaluated the incidence of a composite of death and any cardiovascular (CV) or renal event in 60 RTRs in whom LVH regression was observed and in 40 whose LVH remained unchanged or worsened. Results. During an 8.4 ± 3.5-year follow-up, 8 deaths, 18 CV events and 6 renal events occurred in the entire cohort. Multivariable analysis showed that age [hazard ratio (HR) 1.07, 95% confidence interval (CI) 1.03-1.12 each 1 year, P = 0.002] and LVH regression (HR 0.42, 95% CI 0.22-0.87, P = 0.019) were significant predictors of the composite endpoint. KaplanMeier estimates showed better survival rates in patients in whom actual LVH regression was achieved (P < 0.001, logrank test). Age (HR 1.09, 95% CI 1.03-1.15 each 1 year, P = 0.004), better graft function (HR 0.95, 95% CI 0.91-0.99 each 1 mL/min/1.73 m 2 increase in estimated glomerular filtration rate, P = 0.03) and LVH regression (HR 0.41, 95% CI 0.22-0.79, P = 0.01) were significant predictors of the CV endpoint. Patients with a left ventricular mass index decrease also showed better cardiac event-free survival (P = 0.0022, log-rank test).
I N T RO D U C T I O N
Cardiovascular disease remains the leading cause of death with graft function among renal transplant recipients (RTRs) [1, 2] . Left ventricular hypertrophy (LVH) is observed in ∼50% of patients after transplantation, mainly as an inheritance of the time spent in dialysis before grafting [3] . This elevated prevalence of cardiomyopathy has clinical relevance since it is associated with reduced long-term survival and increased risk for de novo congestive heart failure (CHF) after renal transplantation [4, 5] .
Even though some studies have reported an improvement in cardiomyopathy after successful kidney transplantation [6, 7] , more recent clinical reports have shown that LVH may not regress [8] [9] [10] . In contrast, active pharmacological intervention, mostly by means of antihypertensive medications and especially RAAS blocking agents, proved to be effective in reducing LVH extent or even in returning left ventricular size to normal [11] [12] [13] . Recent studies have shown that mammalian target of rapamycin inhibitors also proved to be effective in regressing LVH in transplanted patients [14, 15] . However, to date, no study has evaluated the effect of LVH regression on hard clinical endpoints such as mortality, incidence of cardiovascular (CV) events and hospitalization rates in RTRs.
The aim of this study was therefore to evaluate the impact of LVH regression on long-term solid clinical endpoints in 100 RTRs enrolled in two previous randomized controlled trials (RCTs) designed to assess the effect of active intervention on asymptomatic post-transplant LVH.
M AT E R I A L S A N D M E T H O D S

Patients
This prospective cohort study was carried out in 100 RTRs who were previously enrolled in two RCTs, both aimed at assessing the effectiveness of active intervention on the regression of LVH in RTRs. Details on these former trials are available elsewhere [13, 16] . In both studies, secondary endpoints were general and CV outcome of enrolled patients. The protocol of both trials conformed to the guidelines of the ethical committee of our institution and was registered at http://isrctn.org (study numbers ISRCTN94487168 and ISRCTN93681079, respectively). Informed consent was obtained from all patients enrolled in both trials.
Briefly, in the first study 70 non-diabetic patients with good graft function, post-transplant LVH and no history of previous CV disease who underwent renal transplantation from a deceased donor in the previous 3-6 months were randomly assigned to receive angiotensin-converting enzyme (ACE) inhibitors (active treatment arm, 36 patients) or no therapy (34 controls). The primary endpoint was left ventricular mass index (LVMi) changes at 18 months. Administration of conventional antihypertensive therapy was permitted in order to achieve adequate blood pressure control [13] .
In the second study, 10 non-diabetic RTRs with good graft function, LVH and no history of previous CV disease who received a transplant from a deceased donor were randomly allocated to everolimus plus reduced exposure cyclosporine (CsA) (active treatment arm), and 20 controls to standard exposure CsA. The endpoint was LVMi changes at 1 year [16] .
In both studies, exclusion criteria were heart failure and ischaemic or valvular heart disease.
Details on the design and results of both studies are reported elsewhere [13, 16] .
In the present study, the long-term clinical outcome of the 60 RTRs in whom LVH regression was observed (regressors) was compared with that of the 40 patients whose LVH remained unchanged or worsened (non-regressors).
Methods
Echocardiography was performed in both studies according to the recommendations of the American Society of Echocardiography (ASE) [17] at baseline, i.e. 3-6 months after transplantation in the first study and 1 month after transplantation in the second study, and again after 18 and 12 months from baseline, respectively. Echotracings were analysed by an expert cardiologist who was blinded to the arm to which each patient was allocated.
Measurements included the end systolic (ESD) and end diastolic (EDD) diameters of the left ventricle (LV), the end diastolic interventricular septum thickness (IVS d ) and the end diastolic thickness of the left ventricular posterior wall (PW d [19] . The percent fractional shortening (%FS) of the LV was calculated as EDD − ESD/ EDD × 100.
Serum creatinine, haemoglobin (Hgb), uric acid, lipids, trough levels for either CsA or tacrolimus and daily urinary protein excretion rate were assessed for each patient. Estimated GFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation [20] .
Each patient underwent both laboratory parameter assessment and office clinical visits by a nephrologist at our institution twice each month during the first 6 months after transplantation, then monthly until the first post-transplant year was completed and every 3-4 months thereafter.
Outcome
The primary long-term endpoint of our study consisted of a composite of all-cause mortality, the time to the first non-fatal CV event [myocardial infarction, coronary revascularization, hospitalization for acute coronary syndrome (ACS), heart failure, arrhythmias, peripheral vascular event or cerebrovascular event], and the time to the start of dialysis due to graft function loss.
The secondary endpoint was a composite of CV death and the time to the first non-fatal CV event (CV endpoint). We considered actual major CV events that required hospitalization, since they could significantly impact the clinical outcome of RTRs.
We also evaluated the incidence of acute rejection episodes and the incidence of new-onset diabetes after transplantation (NODAT) and non-skin malignancies.
All endpoints were adjudicated by an independent group of clinicians who were not involved in either trial and who were unaware of patients' LVMi behaviour.
Causes of death were defined on the basis of the International Classification of Diseases, Ninth Revision (ICD-9) classification, under control of the Italian Istituto Nazionale di Statistica (ISTAT). Major CV events were adjudicated on the basis of hospital records, according to ICD-9 classification. For example, myocardial infarction (MI) was adjudicated as silent MI, S-T elevation MI, non S-T elevation MI, MI requiring percutaneous coronary intervention, MI resulting in death and so on. End-stage renal disease (ESRD) was adjudicated on the day of the first dialysis treatment after graft failure.
Statistical analysis
Results are presented as mean ± SD. For continuous variables, the unpaired Student's t-test was used for between-group comparisons, whereas the paired t-test was used for intragroup comparisons. Fisher's exact test or the χ 2 test, where appropriate, was used to assess differences in the prevalence of non-continuous variables in the two groups. Patients were censored on the date of the last visit if any event was observed.
The prognostic value on outcomes of all covariates at baseline as well as of their changes between final observation and baseline was assessed by univariate Cox proportional hazard regression analysis. A multivariable Cox model was then constructed by including all the variables that were significantly associated with endpoints in the univariate analyses and the pertinent clinical variables whose P-value resulting from univariate analysis, although not significant, was at least ≤0.25 to assess the predictors most significantly associated with the composite endpoint and the CV endpoint. A time indicator was also considered in the multivariable model to adjust for different time assessments (12 versus 18 months) across the two trials.
The HR and 95% CI were estimated with respect to the reference category for each covariate.
The proportional hazard assumption of the Cox model was assessed graphically using a log-log plot for categorical variables and the test based on Schoenfeld residuals for all variables.
Kaplan-Meier survival analysis with log-rank test was used to compare event-free survival curves of patients according to LVMi behaviour. We analysed the effect of LVH regression on outcome and compared regressor with non-regressor RTRs.
Stata (version 11; StataCorp, College Station, TX, USA) and R (R Project for Statistical Computing, Vienna, Austria) were used for analysis.
R E S U LT S
The mean follow-up was 8.4 ± 3.5 years. Table 1 shows baseline data for the 60 regressor and 40 non-regressor RTRs. Regressors had greater LVMi, accounted for by greater EDD and both IVS and left ventricular posterior wall thickness. Interestingly, a greater proportion of patients who had previously been allocated in the active arm was observed among regressors. No other significant differences were found between the two groups.
When analysing changes occurring for each clinical variable between the second observation and baseline, no significant differences were observed between the two groups except LVH regression (Table 2) , which was accounted for by a reduction in both the internal dimension and parietal thickness of the LV (Table 2) .
Long-term outcome During the 8.4 ± 3.5 years of observation, eight deaths occurred (one after 4.1 years due to pancreatic neoplasia, one due to lung cancer after 11.1 years and one due to severe sepsis after 11.8 years in the group of regressor RTRs; one death due to lymphoma after 5.2 years and four cardiac deaths after 5.5, 7.7, 8.5 and 10.2 years, respectively, in the group of non-regressor RTRs).
Six major non-fatal CV events, all requiring hospitalization, were observed among regressor RTRs (3 ACS, 1 MI, 1 arrhythmia and 1 coronary revascularization procedure) and 12 in the group of non-regressors (1 ACS, 2 MI, 4 CHF, 1 arrhythmia, 1 ischaemic peripheral vascular disease, and 3 cerebrovascular accidents), each requiring hospitalization. Six patients lost their graft and resumed dialysis (three in the group of regressors, after 3.1, 3.5 and 6.7 years, and three in the group of non-regressors, after 4.8, 9.2 and 11.8 years). No differences were observed between the two groups with regard to renal event occurrence. The incidence of the composite endpoint was significantly higher in regressors than in nonregressors (P = 0.0022, Fisher's exact test), as was the incidence of fatal and non-fatal CV events (P = 0.0005, Fisher's exact test).
All major events occurred after completion of both trials. During the follow-up period, biopsy-proven acute rejection occurred in five regressor RTRs and in two non-regressors (P = 0.7, Fisher's exact test). Nonetheless, acute rejection did not result in graft loss in any of the five RTRs.
The incidence of NODAT was similar in both groups (16.7% in the group of regressors and 12.5% in the group of non-regressors).
Non-skin malignancies were observed in three patients in the group of regressors and in two patients in the group of nonregressors, with no between-group differences.
Predictors of the composite endpoint by univariate and multivariable Cox regression analysis are presented in Table 3,  whereas Table 4 shows univariate and multivariable Cox regression analysis of the CV endpoint.
On the basis of multivariable analysis, age was significantly associated with the risk of the composite endpoint, whereas more aggressive antihypertensive therapy and having LVH regression were significant predictors of event-free survival (Table 3) . 
O R I G I N A L A R T I C L E
L V H r e g r e s s i o n a n d o u t c o m e o f R T R s
Age was significantly associated with the risk of CV endpoint, whereas more intensive antihypertensive therapy, better graft function and LVH regression were significant predictors of CV event-free survival (Table 4) .
Effect of LVH regression on outcome
Kaplan-Meier curves with log-rank test showed better survival rates for patients in whom LVH regression was observed when compared with non-regressor RTRs, with regard to both the composite (Figure 1 ) and the CV endpoint (Figure 2 ). Significantly better atherosclerotic event-free survival was also observed in RTRs with LVH regression (P = 0.048, log-rank test).
D I S C U S S I O N
To the best of our knowledge, this is the first study to demonstrate that regression of asymptomatic post-transplant LVH portends better general and CV outcome of RTRs. In our study, in fact, patients who actually achieved cardiomyopathy improvement had a lower incidence of the composite endpoint of death and of any CV or renal event, and this important clinical effect was mainly accounted for by a significant reduction in both fatal and non-fatal CV events.
Although the event rate was low in our cohort, it is consistent with findings from the Collaborative Transplant Study (CTS), which enrolled >39 000 RTRs who were followed for >10 years, reporting a 2.3% CV mortality rate [21] . It is conceivable that the low incidence of solid endpoints in our cohort mirrors the absence of overt CV disease at the time of transplantation and the good and stable renal function achieved after grafting.
The effect of LVH regression seems relevant from a clinical point of view since post-transplant LVH is reportedly associated with an increased risk of de novo CHF and reduced long-term survival [4, 5] . LVH is indeed a powerful predictor of subsequent adverse CV prognosis in the general population [22] and in renal patients, where it is strongly associated with impaired diastolic function [23, 24] .
Previous studies carried out on RTRs have also demonstrated that LVH is associated with ventricular repolarization heterogeneity, which is a significant predictor of the risk of subsequent arrhythmias and death [25] , and with systolic dysfunction, which also increases the risk of cardiac events and death F I G U R E 2 : CV endpoint-free survival in 60 RTRs in whom LVH regression was achieved and 40 non-responder RTRs (dotted line) (P = 0.0022). [26] . In our study, we did not evaluate the effect of LVH regression on diastolic function or on LV electrical abnormalities in our patients, in whom only a slight and non-significant improvement in systolic function was observed. Consequently, our study cannot provide any insight into the mechanisms involved in the improved outcome we observed as an effect of cardiomyopathy regression. It is conceivable, however, that LVH regression encompasses all the mechanisms possibly involved in and all the pathophysiological effects induced by its development, thus actually per se proving to be a reliable and powerful predictor of improved clinical outcome. In fact, in our cohort, a wellestablished determinant of RTRs' CV outcome, pulse pressure [27] , was no longer significantly associated with either the composite or the CV endpoint when changes in LVMi were added to the multivariable model.
In the former RCTs, our RTRs with post-transplant LVH allocated to the active arm were administered either ACE inhibitor or everolimus (EVL) on the basis of previous studies that showed the effectiveness of these two medications in reducing LVMi in RTRs [11, 12, 15] .
Although the CTS and the SECRET study failed to demonstrate any positive effect of ACE inhibitors or angiotensin receptor blockers in reducing cardiac mortality and the incidence of major adverse CV events [21, 28] , and in the CEN-TRAL trial no reduction in LVMi was observed in RTRs who were allocated to EVL [29] , in our cohort, active intervention either with ACE inhibitors or EVL induced significant regression of LVH and was associated with more favourable clinical outcome by univariate analysis. Interestingly, this effect disappeared when predictors were analysed by the multivariable model, thus suggesting that LVH regression portends better clinical outcome regardless of the therapeutic strategies that had been adopted to improve cardiomyopathy. In fact, LVH regression was also achieved by some of the RTRs enrolled as controls, thus contributing, though to a lesser degree, to the better clinical outcome resulting from cardiomyopathy regression, which is the most compelling finding of our study.
Although some studies have shown that LVH is also associated with faster renal disease progression toward ESRD in patients with chronic kidney disease [30, 31] , we did not observe a positive effect of LVH regression on renal graft function over time. In our cohort, however, renal graft function was nearly normal at baseline, thus probably limiting the potential effect of LVH regression on renal outcome over time.
By contrast, in our patients, worsening graft function was associated with adverse CV outcome, and this finding is consistent with previous observations in the renal transplant population at large [32, 33] .
Some limitations must be acknowledged in our study. It is a single-centre study with a small cohort. Furthermore, it does not provide data on LV function, especially diastolic LV function, and no data were available on the patients' macrovascular or microvascular conditions, such as calcium score or carotid index.
Last, and more important, like all observational reports, our study may be burdened by selection bias. However, the RCT nature of the previous two trials from which enrolled patients were selected for prolonged longitudinal follow-up makes us confident that this risk could be at least minimized in our study.
According to our findings, regression of LVH appears to be a major objective in RTRs in an effort to improve their general and CV outcomes, and possibly to abate the persistently high rate of death with graft function due to CV disease, regardless of which interventional strategies have been adopted to improve post-transplant cardiomyopathy.
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